Immune therapy combo for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial combines two immune-boosting treatments, Sipuleucel-T and N-803, to see if they can better fight prostate cancer that has spread and stopped responding to hormone therapy. It aims to help your immune system attack the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to other parts of the body, like bones or lymph nodes.
- You have had hormone therapy (like orchiectomy or drugs that lower testosterone) and your testosterone is very low.
- You have not had certain immunotherapies or systemic radiation in the last 6 months.
- You have not had Sipuleucel-T before.
- You are generally in good health, able to do daily activities, and have adequate organ function.
- Your PSA level is 200 or lower.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
This study tests an experimental vaccine that may help your immune system fight prostate cancer cells. If you have low- or intermediate-risk prostate cancer and are under active surveillance, this vaccine might slow or prevent the cancer from growing.
This trial tests a combination of two drugs (REGN5678 and cemiplimab) for men with metastatic castration-resistant prostate cancer that has progressed after at least two prior treatments. The goal is to see if this new combination can help shrink the cancer or slow its growth.
This study combines an immunotherapy drug called sipuleucel-T (which boosts your immune system to fight cancer) with a high-dose testosterone treatment called bipolar androgen therapy. The goal is to see if this combination can help men with advanced prostate cancer that is not responding to usual hormone therapy.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.